A Phase II Pilot Study of Disulfiram and Copper Gluconate in Patients With Metastatic Pancreatic Cancer and Rising CA-19-9 Levels While Receiving Abraxane-Gemcitabine or FOLFIRINOX or Single-Agent Gemcitabine
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Aug 2019
Price : $35 *
At a glance
- Drugs Copper-gluconate/disulfiram (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 05 Aug 2019 Planned End Date changed from 1 Dec 2020 to 1 Jul 2021.
- 05 Aug 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.
- 05 Aug 2019 Planned initiation date changed from 30 Jun 2019 to 30 Aug 2019.